000281801 001__ 281801
000281801 005__ 20251022104759.0
000281801 0247_ $$2doi$$a10.1017/neu.2025.10036
000281801 0247_ $$2pmid$$apmid:40958469
000281801 0247_ $$2ISSN$$a0924-2708
000281801 0247_ $$2ISSN$$a1601-5215
000281801 037__ $$aDZNE-2025-01187
000281801 041__ $$aEnglish
000281801 082__ $$a610
000281801 1001_ $$00000-0001-7322-1195$$aEndres, Dominique$$b0
000281801 245__ $$aMR spectroscopic imaging and its association with EEG, CSF, and psychometric/neuropsychological findings in patients with suspected autoimmune psychosis spectrum syndromes.
000281801 260__ $$aCambridge$$bCambridge Univ. Press$$c2025
000281801 3367_ $$2DRIVER$$aarticle
000281801 3367_ $$2DataCite$$aOutput Types/Journal article
000281801 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761122780_30529
000281801 3367_ $$2BibTeX$$aARTICLE
000281801 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281801 3367_ $$00$$2EndNote$$aJournal Article
000281801 520__ $$aAutoimmune psychosis (AP) and other autoimmune psychiatric syndromes (APS) are associated with central nervous system antibodies. This study investigated related magnetic resonance spectroscopic imaging (MRSI) signatures and their correlations with electroencephalography (EEG), cerebrospinal fluid (CSF), and psychometric/neuropsychological measures.Twenty-eight adults with suspected antibody-positive AP spectrum syndromes were compared with 28 matched healthy controls. Inclusion in the patient group was based on the APS concept, resulting in a heterogeneous group with uniform autoimmunity. MRSI was performed using a spiral-encoded Mescher-Garwood localized adiabatic selective refocusing 3D-MRSI sequence. Glutamate+glutamine (Glx), gamma-aminobutyric acid (GABA), total N-acetylaspartate (tNAA), and total creatine (tCr) were reported as ratios to tNAA and/or tCr. EEG was analyzed for intermittent rhythmic delta/theta activity (IRDA/IRTA) using independent component analysis.No significant differences in Glx, GABA, tNAA, or tCr ratios were observed between patients and controls. Correlation analyses in patients showed a trend for a negative association of the IRDA/IRTA rate before hyperventilation with the GABA/tCr ratio in both hippocampi and with the GABA/tNAA ratio in the left hippocampus and Glx/tCr ratio in the right putamen and pallidum. Significant positive correlations were observed between inflammatory CSF markers (white blood cell count and IgG Index) and GABA/tCr and GABA/tNAA ratios in the left caudate nucleus and right isthmus cingulate and thalamus, as well as between negative symptoms in PANSS and higher GABA/tCr ratios in the right putamen.No group differences were identified; however, correlations suggest a link between neuroinflammatory CSF markers and negative symptoms with GABAergic signaling in patients. Multimodal diagnostic approaches may provide a better understanding of the link between neuroinflammation, neurochemistry, and EEG slowing.
000281801 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281801 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281801 650_7 $$2Other$$aAutoantibody
000281801 650_7 $$2Other$$aMRS
000281801 650_7 $$2Other$$abrain
000281801 650_7 $$2Other$$aneurochemistry
000281801 650_7 $$2Other$$aneuroinflammation
000281801 7001_ $$aMatteit, Isabelle$$b1
000281801 7001_ $$avon Zedtwitz, Katharina$$b2
000281801 7001_ $$aFeige, Bernd$$b3
000281801 7001_ $$aSchlump, Andrea$$b4
000281801 7001_ $$aReisert, Marco$$b5
000281801 7001_ $$aNickel, Kathrin$$b6
000281801 7001_ $$aRunge, Kimon$$b7
000281801 7001_ $$aDomschke, Katharina$$b8
000281801 7001_ $$aPerlov, Evgeniy$$b9
000281801 7001_ $$aRau, Alexander$$b10
000281801 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b11$$udzne
000281801 7001_ $$aLange, Thomas$$b12
000281801 7001_ $$aTebartz van Elst, Ludger$$b13
000281801 7001_ $$aMaier, Simon J$$b14
000281801 773__ $$0PERI:(DE-600)2077830-2$$a10.1017/neu.2025.10036$$gp. 1 - 36$$pe88$$tActa neuropsychiatrica$$v37$$x0924-2708$$y2025
000281801 8564_ $$uhttps://pub.dzne.de/record/281801/files/DZNE-2025-01187.pdf$$yRestricted
000281801 8564_ $$uhttps://pub.dzne.de/record/281801/files/DZNE-2025-01187.pdf?subformat=pdfa$$xpdfa$$yRestricted
000281801 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000281801 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281801 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000281801 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-11$$wger
000281801 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPSYCHIATR : 2022$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000281801 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000281801 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000281801 980__ $$ajournal
000281801 980__ $$aEDITORS
000281801 980__ $$aVDBINPRINT
000281801 980__ $$aI:(DE-2719)1810003
000281801 980__ $$aUNRESTRICTED